Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | CLK1 | P49759 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18392699 | 0.90 | RAB9A (0.56) | RAB9ANPC1CLK1MAPTTP53 | |
| SCHEMBL338133 | 0.86 | CYP4F2 (0.51) | RAB9ANPC1CLK1POLBCYP4F2 | |
| SCHEMBL4521074 | 0.86 | RAB9A (0.52) | RAB9ANPC1MAPTCASP3CASP7 | |
| SCHEMBL4140012 | 0.84 | RAB9A (0.58) | RAB9ANPC1MAPTPOLBTP53 | |
| SCHEMBL4678364 | 0.81 | RAB9A (0.52) | RAB9ANPC1CLK1MAPTCASP3 | |
| SCHEMBL2777357 | 0.79 | RAB9A (0.52) | RAB9ANPC1MAPTCASP3CASP7 | |
| SCHEMBL1403662 | 0.79 | FABP4 (0.56) | RAB9ANPC1MAPTCASP3CASP7 | |
| SCHEMBL31478141 | 0.79 | LMNA (0.46) | RAB9ANPC1MAPTCYP4F2CYP4A11 | |
| SCHEMBL852863 | 0.78 | ALDH1A1 (0.56) | RAB9ANPC1CLK1MAPTPOLB | |
| SCHEMBL7986608 | 0.78 | CYP3A4 (0.61) | RAB9ANPC1MAPTTP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329755-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | DUNN JAMES PATRICK | 2010-02-18 | — | — | US | disclosed |
| US-7625949-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1742908-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009006413-A1 | SUBSTITUTED PYRROLIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009006413-A1 | SUBSTITUTED PYRROLIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005431-A1 | SUBSTITUTED PYRROLIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005431-A1 | SUBSTITUTED PYRROLIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005431-A1 | SUBSTITUTED PYRROLIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-7166738-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1742908-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005102989-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
| US-20050239880-A1 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
| EP-0132130-B1 | AROYL BENZOFURAN AND BENZOTHIOPHENE ACETIC AND PROPIONIC ACIDS PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1990-03-07 | — | — | EP | disclosed |
| US-4816473-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS | SYNTEX (U.S.A.) INC. (US) | 1989-03-28 | — | — | US | disclosed |
| US-4780480-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1988-10-25 | — | — | US | disclosed |
| EP-0132130-A2 | Aroyl benzofuran and benzothiophene acetic and propionic acids processes for their production and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1985-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | CCR5, CXCR4, CCR1 | RAB9A 912/4885NPC1 112/4885CLK1 4873/4885 |
| US-20050239880-A1 | Methods for treating retroviral infections | CCR5, CD38, CD4 | RAB9A 985/4885NPC1 378/4885CLK1 4864/4885 |
| US-20090005431-A1 | SUBSTITUTED PYRROLIDINES | CHRM3, CHRM2, CHRM5 | RAB9A 1053/4885NPC1 1668/4885CLK1 4498/4885 |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | RPP30, PNP, RTF1 | RAB9A 1060/4885NPC1 737/4885CLK1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.